October 06, 2026
The information on this site is not intended to take the place of your doctor or other healthcare professionals. It is a resource to help you make the best decisions and get the most from the medical services available to you. A licensed physician should be consulted for diagnosis and treatment of all medical conditions.
On Aug. 31, 2026, Amneal Pharmaceuticals LLC initiated a voluntary recall of exenatide injection, 250 mcg/mL, due to the potential for some autoinjector pens to be distributed without medication. Exenatide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Use of an affected device may fail to deliver the intended dose, leading to reduced glucose-lowering effects and potentially inadequate blood sugar control. For more information about the recall, see here.
Last updated: October 06, 2026